Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
AltruBio Inc. logo — Novel Therapeutics for Immunological Diseases

AltruBio Inc.

Novel Therapeutics for Immunological Diseases

Founded 2020 United States San Francisco, United States 28 employees Series B Total: $327.61M Biotechnology, Health Care

General Information

Company Name AltruBio Inc.
Founded Year 2020
Location United States San Francisco, United States +1
Employees 28
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when AltruBio Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

AltruBio Inc. recently secured a substantial $225 million Series B funding round in May 2024, signaling strong investor confidence in its novel immune-modulator pipeline. This significant capital influx, backed by prominent biotech investors, is poised to accelerate the development of their biologic treatments for immunological diseases and various cancers. Concurrently, the company is actively advancing clinical studies and planning for future scientific engagement, indicating a strategic push towards pipeline progression and industry visibility.

Signal Types
Funding R&D Market Engagement
Strategic Labels
Pipeline Acceleration Clinical Development Investor Validation
Next Move: Clinical Trials
·
Impact: 9/10
·
Ideal For: Biopharma Growth Investors — Series B/C

About AltruBio Inc.

AltruBio Inc., founded in 2020, is carving out a niche in the Biotechnology and Health Care sectors with its mission to develop Novel Therapeutics for Immunological Diseases. This United States-based company is pioneering first-in-class immune-modulators targeting key areas in #immunology and #inflammation, driven by a world-class team with profound expertise in the fields of immunology and drug development.

Their recent $225.00M Series B funding on 21 May 2024 highlights significant investor confidence. The impressive investment round drew participation from notable investors including Blackstone Group, RA Capital Management, aMoon, Delos Capital, Soleus Capital, Cormorant Asset Management, and Biotechnology Value Fund. This capital infusion is expected to accelerate AltruBio's development pipeline, amplifying its ability to deliver innovative solutions to pressing unmet medical needs in immunology.

Taxonomy: immunological diseases, immune-modulators, biologic treatments, antibody therapeutics, cancer treatment, immune-related inflammatory diseases, drug development, autoimmune diseases, pancreatic cancer, stomach cancer, colorectal cancer, ovarian cancer, lung cancer, solid tumors, novel therapeutics

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor Investor
•••• •••• 		21 May 2024
Series A •••••• 3
Investor Investor
•••• •••• 		15 Apr 2021
Series C •••••• - 27 Aug 2014
Series B •••••• - 18 Jul 2013
Series A •••••• - 19 Jun 2012

AltruBio Inc. Alternatives & Competitors

AltruBio Inc. vs
AnaptysBio
AnaptysBio United States

Transforming patient health by delivering innovative immunology therapeutics.

IPO
144 employees
Biotechnology, Health Care
Compare AltruBio Inc. vs AnaptysBio
AltruBio Inc. vs
Cugene Inc.
Cugene Inc. United States

One Passion, One Goal, Many Cures.

16 employees
Biotechnology, Health Care
Compare AltruBio Inc. vs Cugene Inc.
AltruBio Inc. vs
Autonomous Therapeutics
Autonomous Therapeutics United States

Precision medicines via a new class of RNA

11 employees
Biotechnology, Prop Tech
Compare AltruBio Inc. vs Autonomous Therapeutics

FAQ About AltruBio Inc.

Novel Therapeutics for Immunological Diseases
AltruBio Inc. was founded in 2020.
AltruBio Inc. is headquartered in San Francisco, United States.
AltruBio Inc. operates in the following industries: Biotechnology, Health Care.
AltruBio Inc. has approximately 28 employees.
AltruBio Inc. has completed 5 funding rounds, raising a total of $327.61M. The latest funding stage is Series B.
Top alternatives and competitors to AltruBio Inc. include AnaptysBio, Cugene Inc., Autonomous Therapeutics, ImmunoBiome Inc., Cogen Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AltruBio Inc. and AnaptysBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AltruBio Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy